This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
VIM · Western blot design guide
VIM Western Blot Planning Guide
Plan a VIM Western blot around the catalog-observed 53.7 kDa band, image-backed PB9359 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
VIM Western Blot Experimental Design Guide
Expected bands, documented protocol parameters, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 53.7 kDa | |
| Observed band | Not reported — verify product WB image | |
| Gel | 12-15% | |
| Positive control | Adipose tissue | |
| Negative control | Duodenum |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 53.7 kDa |
| ⓘ | Localization | Cytoplasm / Cytoplasm, cytoskeleton |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Human / Mouse / Rat |
Section 1
Real Curated VIM Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Adipose tissue |
| Gel % | 12-15% |
| Load | 20-30 µg total protein per lane |
| Transfer | Semi-dry, standard transfer |
| Membrane | 0.45 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | PB9359 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 2
What Is the Expected VIM Western Blot Band Size?
Use the product-observed 53.7 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 53.7 kDa | Matches the authoritative product WB observation. |
| 53.7 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected VIM appearancePlan around 53.7 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 53.7 kDa; use this as the primary experimental expectation. |
| Calculated mass | 53.7 kDa from UniProt P08670; retain as context. |
| Gel selection | 12-15%; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with PB9359. |
| Situation | Likely cause | Next action |
|---|---|---|
| 53.7 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing VIM band
PB9359 · VIM
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for VIM Western blot
🧪Use Adipose tissue as the first positive-control candidate and Duodenum as the HPA Not detected negative candidate.
Positive control: Adipose tissue (High)
Negative control: Duodenum (Not detected)
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for VIM
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Reported tissue cells | High | Protein (HPA) | HPA → |
| Breast | Reported tissue cells | High | Protein (HPA) | HPA → |
| Appendix | Reported tissue cells | High | Protein (HPA) | HPA → |
| Bone marrow | Reported tissue cells | High | Protein (HPA) | HPA → |
Section 3
Advanced VIM Western Blot Tips
Deeper troubleshooting and optimisation questions for VIM, answered from its protein features.
Which band should guide the blot?
Use 53.7 kDa, the observation attached to the authoritative PB9359 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 53.7 kDa expectation.
Which positive control should I start with?
Start with Adipose tissue, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Duodenum as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 12-15% consistently across the quick facts, protocol table, and poster.
What transfer method to use for VIM Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should PB9359 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
Compare only the supplied target-verified records: PMC5839369, PMC9268588, PMC10067404.
Boster reagents
VIM Western Blot Reagents
Human/Mouse/Rat-reactive VIM Western blot reagents with authoritative product imagery.
Real WB data
Anti-Vimentin Antibody Picoband®
Cat # PB9359
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt P08670
- Human Protein Atlas — VIM
- PB9359 product record
- PMC5839369 — CD44 exerts a functional role during EMT induction in cisplatin-resistant head and neck cancer cells.
- PMC9268588 — Phosphorylation of ERK-Dependent NF-κB Triggers NLRP3 Inflammasome Mediated by Vimentin in EV71-Infected Glioblastoma Cells.
- PMC10067404 — Limb expression 1-like protein promotes epithelial-mesenchymal transition and epidermal growth factor receptor-tyrosine kinase inhibitor resistance via nucleolin-mediated ribosomal RNA synthesis in non-small cell lung cancer.